1159 related articles for article (PubMed ID: 14598611)
21. Comparison of D&C and hysterectomy pathologic findings in endometrial cancer patients.
Wang X; Huang Z; Di W; Lin Q
Arch Gynecol Obstet; 2005 Jul; 272(2):136-41. PubMed ID: 15666177
[TBL] [Abstract][Full Text] [Related]
22. bcl-2 and p53 in endometrial adenocarcinoma.
Taskin M; Lallas TA; Barber HR; Shevchuk MM
Mod Pathol; 1997 Jul; 10(7):728-34. PubMed ID: 9237185
[TBL] [Abstract][Full Text] [Related]
23. The use of an immunocytochemical double-labeling staining can display the distribution of Bcl-2/Ki-67 cells in endometrial adenocarcinomas as well as in normal endometrium.
Mourtzikou A; Kosmas K; Marouga A; Stamouli M; Pouliakis A; Karakitsos P
Clin Lab; 2012; 58(1-2):133-44. PubMed ID: 22372356
[TBL] [Abstract][Full Text] [Related]
24. Prognostic significance of ER, PR, Ki67, c-erbB-2, and p53 in endometrial carcinoma.
Suthipintawong C; Wejaranayang C; Vipupinyo C
J Med Assoc Thai; 2008 Dec; 91(12):1779-84. PubMed ID: 19133508
[TBL] [Abstract][Full Text] [Related]
25. Ki-67, Bcl-2 and p53 expression in endometrial polyps and in the normal endometrium during the menstrual cycle.
Maia H; Maltez A; Studart E; Athayde C; Coutinho EM
BJOG; 2004 Nov; 111(11):1242-7. PubMed ID: 15521869
[TBL] [Abstract][Full Text] [Related]
26. Immunohistochemical localization of metallothionein in endometrial lesions.
Ioachim EE; Kitsiou E; Carassavoglou C; Stefanaki S; Agnantis NJ
J Pathol; 2000 Jul; 191(3):269-73. PubMed ID: 10878548
[TBL] [Abstract][Full Text] [Related]
27. Stepwise abnormality of sex steroid hormone receptors, tumor suppressor gene products (p53 and Rb), and cyclin E in uterine endometrioid carcinoma.
Li SF; Shiozawa T; Nakayama K; Nikaido T; Fujii S
Cancer; 1996 Jan; 77(2):321-9. PubMed ID: 8625241
[TBL] [Abstract][Full Text] [Related]
28. Immunofluorometric study of Bcl-2 and Bax expression in clinical fresh tumor samples from breast cancer patients.
Martínez-Arribas F; Núñez-Villar MJ; Lucas AR; Sánchez J; Tejerina A; Schneider J
Anticancer Res; 2003; 23(1B):565-8. PubMed ID: 12680147
[TBL] [Abstract][Full Text] [Related]
29. Expression of cyclin D1 in normal, hyperplastic and neoplastic endometrium and its correlation with Ki-67 and clinicopathological variables.
Ozuysal S; Oztürk H; Bilgin T; Filiz G
Arch Gynecol Obstet; 2005 Feb; 271(2):123-6. PubMed ID: 14740230
[TBL] [Abstract][Full Text] [Related]
30. Different proliferative patterns characterize different preinvasive breast lesions.
Viacava P; Naccarato AG; Bevilacqua G
J Pathol; 1999 Jul; 188(3):245-51. PubMed ID: 10419590
[TBL] [Abstract][Full Text] [Related]
31. The differential expression of oestrogen receptors, progesterone receptors, Bcl-2 and Ki67 in endometrial polyps.
Taylor LJ; Jackson TL; Reid JG; Duffy SR
BJOG; 2003 Sep; 110(9):794-8. PubMed ID: 14511960
[TBL] [Abstract][Full Text] [Related]
32. Immunohistochemical profile of endometrial adenocarcinoma: a study of 61 cases and review of the literature.
Kounelis S; Kapranos N; Kouri E; Coppola D; Papadaki H; Jones MW
Mod Pathol; 2000 Apr; 13(4):379-88. PubMed ID: 10786803
[TBL] [Abstract][Full Text] [Related]
33. Utility of Ki-67, p53, Bcl-2, and Cox-2 biomarkers for low-grade endometrial cancer and disordered proliferative/benign hyperplastic endometrium by imprint cytology.
Apostolou G; Apostolou N; Biteli M; Kavantzas N; Patsouris E; Athanassiadou P
Diagn Cytopathol; 2014 Feb; 42(2):134-42. PubMed ID: 23729350
[TBL] [Abstract][Full Text] [Related]
34. Correlation of proliferation indices, apoptosis, and related oncogene expression (bcl-2 and c-erbB-2) and p53 in proliferative, hyperplastic, and malignant endometrium.
Ioffe OB; Papadimitriou JC; Drachenberg CB
Hum Pathol; 1998 Oct; 29(10):1150-9. PubMed ID: 9781657
[TBL] [Abstract][Full Text] [Related]
35. Expression of bcl-2, bax-xL, and bcl-xS in endometrial and cervical tissues.
Mozzetti S; Ferrandina G; Marone M; D'Ingiullo F; Fruscella E; De Pasqua A; Mancuso S; Scambia G
Cancer Detect Prev; 2000; 24(6):536-41. PubMed ID: 11198267
[TBL] [Abstract][Full Text] [Related]
36. Correlation between proliferation markers: PCNA, Ki-67, MCM-2 and antiapoptotic protein Bcl-2 in colorectal cancer.
Guzińska-Ustymowicz K; Pryczynicz A; Kemona A; Czyzewska J
Anticancer Res; 2009 Aug; 29(8):3049-52. PubMed ID: 19661314
[TBL] [Abstract][Full Text] [Related]
37. p53 overexpression and bcl-2 persistence in endometrial carcinoma: comparison of papillary serous and endometrioid subtypes.
Zheng W; Cao P; Zheng M; Kramer EE; Godwin TA
Gynecol Oncol; 1996 May; 61(2):167-74. PubMed ID: 8626128
[TBL] [Abstract][Full Text] [Related]
38. Correlation between genetic and biological aspects in primary non-metastatic breast cancers and corresponding synchronous axillary lymph node metastasis.
D'Andrea MR; Limiti MR; Bari M; Zambenedetti P; Montagutti A; Ricci F; Pappagallo GL; Sartori D; Vinante O; Mingazzini PL
Breast Cancer Res Treat; 2007 Mar; 101(3):279-84. PubMed ID: 16835704
[TBL] [Abstract][Full Text] [Related]
39. Expression of the apoptosis-related genes Bcl-2 and p53 in clinical samples from endometrial carcinoma patients.
González-Rodilla I; Verna V; Muñoz AB; Estévez J; Boix M; Schneider J
Anticancer Res; 2011 Dec; 31(12):4191-3. PubMed ID: 22199279
[TBL] [Abstract][Full Text] [Related]
40. Expression of heat shock proteins HSP70 and HSP90 in endometrial carcinomas. Correlation with clinicopathology, sex steroid receptor status, and p53 protein expression.
Nanbu K; Konishi I; Komatsu T; Mandai M; Yamamoto S; Kuroda H; Koshiyama M; Mori T
Cancer; 1996 Jan; 77(2):330-8. PubMed ID: 8625242
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
